Array BioPharma

Array BioPharma
Company type	Subsidiary
Traded as	Nasdaq: ARRY
Industry	Oncology; Medication
Founded	1998; 26 years ago
Founder	Drs. Tony Piscopio; Kevin Koch; David Snitman; K.C. Nicolaou;
Headquarters	Boulder, Colorado, United States
Revenue	$173.8 million (2018)
Parent	Pfizer
Website	www.arraybiopharma.com

Array BioPharma is an American clinical stage, pharmaceutical company that focuses on oncology medication headquartered in Boulder, Colorado. The company is currently a subsidiary of Pfizer after being acquired for $11 billion in 2019.

History

In 1998, the company was founded by Drs. Tony Piscopio, Kevin Koch, David Snitman, and K.C. Nicolaou.^[1]

In November 2000, the company became a public company via an initial public offering.^[2]

In June 2019, Pfizer acquired the company for approximately $11 billion.^[3]

Discovery of FDA Approved Small Molecules

MEKTOVI (Binimetinib) - selective MEK inhibitor - Approved 2018, acquired by Pfizer
TUKYSA (Tucatinib) - HER2 inhibitor - Approved 2020, owned by Seagen (Seattle Genetics)
BRAFTOVI (Encorafenib) - BRAF inhibitor - Approved 2018, acquired by Pfizer
KRAZATI (Adagrasib) - KRasG12C mutation inhibitor - Approved 2022, collaboration with Mirati Therapeutics
KOSELUGO (Selumetinib) - MEK1/2 inhibitor - Approved 2020, licensed by Astrazeneca
VITRAKVI (Larotrectinib) - TRK Inhibitor - Approved 2018, licensed by Loxo Oncology (Eli Lilly)

References

^ "Co-Founder Of Array BioPharma, Inc. To Lead New Korean Out-Sourcing Chemistry Company". BioSpace. Retrieved 2020-07-28.
^ "Array IPO up 17%". CNN. November 17, 2000.
^ "Pfizer acquires Array BioPharma, valued at $11.4 billion". Rappler. 18 June 2019. Retrieved 2020-07-29.

[1] "Co-Founder Of Array BioPharma, Inc. To Lead New Korean Out-Sourcing Chemistry Company". BioSpace. Retrieved 2020-07-28.

[2] "Array IPO up 17%". CNN. November 17, 2000.

[3] "Pfizer acquires Array BioPharma, valued at $11.4 billion". Rappler. 18 June 2019. Retrieved 2020-07-29.

[1]

[2]

[3]